FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890906559> ?p ?o ?g. }

• W2890906559 endingPage "293" @default.
• W2890906559 startingPage "286" @default.
• W2890906559 abstract "Osteoporosis is a systemic skeletal disease of fragility fractures due to the loss of mass and deterioration of the microarchitecture of bone. The aim of the study was to assess the osteogenic effects and the underlying mechanisms of the combined administration of You-Gui Yin (YGY) and Raloxifene hydrochloride (RLX) in ovariectomized (OVX) mice. First, a classic animal model was used to mimic postmenopausal osteoporosis through the removal of the ovary of mice. Second, the OVX mice were administered YGY, RLX, and YGY + RLX for 12 weeks. Next, the bone microtomographic histomorphometry and bone mineral density (BMD) were assessed by micro-CT, and the biochemical markers of procollagen type I N-terminal propeptide (P1NP) and beta-isomerized C-telopeptide (β-CTX) in serum were assessed. Finally, primary bone marrow stromal cells (BMSCs) were isolated from the tibia and cultured to evaluate cell proliferation and osteogenic differentiation. The results showed that BMD on the YGY + RLX group was higher than that on the RLX group (p < 0.05) and did not have a significant difference when compared with the sham group. Notably, the YGY + RLX group had a dramatically increased trabecular number (Tb.N) compared with that of the YGY group (p < 0.05). Moreover, the BV/TV (bone volume/total volume) and Tb.N in the YGY + RLX group were higher than that in the RLX group (p < 0.05), and the Tb.Sp (trabecular separation) was lower than that in the RLX group (p < 0.05). Moreover, the serum level of P1NP from the YGY + RLX group dramatically increased when compared with that from the YGY and RLX groups (YGY group: p < 0.05; RLX groups: p < 0.01). Notably, there was no significant difference between the YGY and YGY + RLX groups. In addition, cell proliferation from the co-administration of YGY and RLX was clearly higher than a single use of YGY and RLX (p < 0.01, respectively). The ALP/BCA (alkaline phosphatase/bicinchoninic acid) in the YGY + RLX group was higher than that in the RLX group (p < 0.01). Overall, co-administered YGY and RLX could partially attenuate bone loss and were more effective than individually using either one; this outcome might be associated with the proliferation and osteogenic differentiation of BMSCs." @default.
• W2890906559 created "2018-09-27" @default.
• W2890906559 creator A5014722446 @default.
• W2890906559 creator A5036030375 @default.
• W2890906559 creator A5039024839 @default.
• W2890906559 creator A5055031396 @default.
• W2890906559 creator A5055242868 @default.
• W2890906559 creator A5062875846 @default.
• W2890906559 creator A5066418453 @default.
• W2890906559 creator A5078250528 @default.
• W2890906559 creator A5080318018 @default.
• W2890906559 date "2019-02-01" @default.
• W2890906559 modified "2023-10-17" @default.
• W2890906559 title "Combined administration on You-Gui Yin and low-dose Raloxifene partially attenuates the bone loss in ovariectomized mice through the proliferation and osteogenic differentiation of bone marrow stromal cells" @default.
• W2890906559 cites W2006682979 @default.
• W2890906559 cites W2013724724 @default.
• W2890906559 cites W2019213708 @default.
• W2890906559 cites W2021439831 @default.
• W2890906559 cites W2021600569 @default.
• W2890906559 cites W2022283832 @default.
• W2890906559 cites W2035252733 @default.
• W2890906559 cites W2038083756 @default.
• W2890906559 cites W2040374043 @default.
• W2890906559 cites W2072915185 @default.
• W2890906559 cites W2090524456 @default.
• W2890906559 cites W2102179078 @default.
• W2890906559 cites W2104524606 @default.
• W2890906559 cites W2149938933 @default.
• W2890906559 cites W2157745689 @default.
• W2890906559 cites W2159239273 @default.
• W2890906559 cites W2167593886 @default.
• W2890906559 cites W2237213079 @default.
• W2890906559 cites W2300014751 @default.
• W2890906559 cites W2301850895 @default.
• W2890906559 cites W2419522160 @default.
• W2890906559 cites W2583645070 @default.
• W2890906559 cites W2607178832 @default.
• W2890906559 cites W2620789460 @default.
• W2890906559 cites W889226931 @default.
• W2890906559 doi "https://doi.org/10.1016/j.phymed.2018.09.014" @default.
• W2890906559 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30668409" @default.
• W2890906559 hasPublicationYear "2019" @default.
• W2890906559 type Work @default.
• W2890906559 sameAs 2890906559 @default.
• W2890906559 citedByCount "7" @default.
• W2890906559 countsByYear W28909065592020 @default.
• W2890906559 countsByYear W28909065592022 @default.
• W2890906559 countsByYear W28909065592023 @default.
• W2890906559 crossrefType "journal-article" @default.
• W2890906559 hasAuthorship W2890906559A5014722446 @default.
• W2890906559 hasAuthorship W2890906559A5036030375 @default.
• W2890906559 hasAuthorship W2890906559A5039024839 @default.
• W2890906559 hasAuthorship W2890906559A5055031396 @default.
• W2890906559 hasAuthorship W2890906559A5055242868 @default.
• W2890906559 hasAuthorship W2890906559A5062875846 @default.
• W2890906559 hasAuthorship W2890906559A5066418453 @default.
• W2890906559 hasAuthorship W2890906559A5078250528 @default.
• W2890906559 hasAuthorship W2890906559A5080318018 @default.
• W2890906559 hasConcept C121608353 @default.
• W2890906559 hasConcept C126322002 @default.
• W2890906559 hasConcept C134018914 @default.
• W2890906559 hasConcept C16930146 @default.
• W2890906559 hasConcept C170033053 @default.
• W2890906559 hasConcept C185592680 @default.
• W2890906559 hasConcept C2776541429 @default.
• W2890906559 hasConcept C2776886416 @default.
• W2890906559 hasConcept C2777164284 @default.
• W2890906559 hasConcept C2779889926 @default.
• W2890906559 hasConcept C2780007613 @default.
• W2890906559 hasConcept C530470458 @default.
• W2890906559 hasConcept C71924100 @default.
• W2890906559 hasConcept C8264082 @default.
• W2890906559 hasConcept C84606932 @default.
• W2890906559 hasConceptScore W2890906559C121608353 @default.
• W2890906559 hasConceptScore W2890906559C126322002 @default.
• W2890906559 hasConceptScore W2890906559C134018914 @default.
• W2890906559 hasConceptScore W2890906559C16930146 @default.
• W2890906559 hasConceptScore W2890906559C170033053 @default.
• W2890906559 hasConceptScore W2890906559C185592680 @default.
• W2890906559 hasConceptScore W2890906559C2776541429 @default.
• W2890906559 hasConceptScore W2890906559C2776886416 @default.
• W2890906559 hasConceptScore W2890906559C2777164284 @default.
• W2890906559 hasConceptScore W2890906559C2779889926 @default.
• W2890906559 hasConceptScore W2890906559C2780007613 @default.
• W2890906559 hasConceptScore W2890906559C530470458 @default.
• W2890906559 hasConceptScore W2890906559C71924100 @default.
• W2890906559 hasConceptScore W2890906559C8264082 @default.
• W2890906559 hasConceptScore W2890906559C84606932 @default.
• W2890906559 hasFunder F4320321001 @default.
• W2890906559 hasLocation W28909065591 @default.
• W2890906559 hasLocation W28909065592 @default.
• W2890906559 hasOpenAccess W2890906559 @default.
• W2890906559 hasPrimaryLocation W28909065591 @default.
• W2890906559 hasRelatedWork W2035195447 @default.
• W2890906559 hasRelatedWork W2110116791 @default.
• W2890906559 hasRelatedWork W2372551535 @default.
• W2890906559 hasRelatedWork W2383524245 @default.
• W2890906559 hasRelatedWork W2386420363 @default.

• next